PTC Therapeutics Inc (STU:BH3)
€ 36.8 0 (0%) Market Cap: 2.89 Bil Enterprise Value: 2.25 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 66/100

PTC Therapeutics Inc CHMP Opinion on Translarna Call Transcript

Sep 15, 2023 / 12:45PM GMT
Release Date Price: €34.4 (-2.27%)
Operator

Good day, and thank you for standing by. Welcome to today's conference call CHMP opinion on Translarna.

(Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your host today, Ron Aldridge, Senior Director, Investor Relations. Please go ahead.

Ron Aldridge

Good morning, and thank you for joining us today to discuss the CHMP opinion on Translarna. I'm joined today by our Chief Executive Officer, Dr. Matthew Klein.

Today's call will include forward-looking statements based on our current expectations, including with respect to PTC's plans for interactions with the European Medicines Agency and the outcome of any reexamination process. Please take a moment to review the press release that we issued this morning, which contains more information regarding forward-looking statements.

Our actual results could materially differ from these forward-looking statements, as such statements are subject to risks that can materially and adversely affect our business

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot